IngredientsHydrochloric acid (HCl) is the main constituent of gastric acid and is secreted naturally by parietal cells of the stomach. As a dietary supplement, exogenous hydrochloric acid is not administered in its pure liquid form; instead, it is delivered almost exclusively as betaine hydrochloride (betaine HCl), a stable salt that releases free hydrochloric acid upon dissolution in the aqueous environment of the stomach.
Betaine HCl is the hydrochloride salt of betaine, a different but important supplemental compound. It is important to distinguish between betaine hydrochloride and betaine (or trimethylglycine, TMG) as these agents have very different chemistry and clinical indications. The non-acidic betaine is used primarily as a methyl donor, especially to treat homocystinuria (for which it is approved as a prescription drug). In contrast, betaine HCl readily releases H⁺ in an aqueous environment (approximately 0.65 mmol per 100 mg). Confusion between these two compounds is common, even noted recently in a medication error report.
The supplement is known under numerous synonyms. These include: Acide Chlorhydrique de Bétaïne, Betaine Chlorhydrate, Betaine HCl, Betaine Hydrochloric Acid, Chlorhidrato de Betaína, Chlorhydrate de Bétaïne, Chlorhydrate de Triméthylglycine, Glycine Betaine Hydrochloric Acid, TMG, Trimethyl Glycine, Trimethylglycine, and Trimethylglycine hydrochloride.
Betaine is a nutritional compound extracted from certain plants like sugar beets. Betaine hydrochloride is an acidic version of this compound that acts as a source of hydrochloric acid in people with low levels of stomach acid. Although the betaine moiety is naturally found in beets and other plants, the combined betaine hydrochloride salt itself is manufactured synthetically. Betaine hydrochloride is a chemical substance made in a laboratory. Synthetic betaine is indistinguishable from natural material.
Common preparation forms:
A second, less commonly encountered form is glutamic acid hydrochloride. Glutamic acid hydrochloride is another example of an HCl salt used for this purpose. However, betaine hydrochloride is by far the predominant commercial form.
Betaine hydrochloride used to be included in over-the-counter (OTC) products as a "stomach acidifier and digestive aid." Betaine hydrochloride was sold over-the-counter (OTC) as a purported gastric aid in the United States. This use predates modern pharmacological understanding and reflected a long-standing tradition among practitioners of what was then called "regular medicine" of supplementing gastric acid in patients believed to suffer from insufficient secretion. The concept of hypochlorhydria—inadequate production of stomach acid—was recognized clinically in the late 19th and early 20th centuries, when hydrochloric acid preparations, including dilute HCl solutions and its various salts, were prescribed as digestive aids.
Bitter-tasting plants or plant extracts (bitters) have been commonly used in many herbal medicinal traditions to promote digestion and/or to relieve digestive complaints, and mechanisms have been studied in in vitro models for the potential role of bitters in acid secretion. These botanical preparations, used across European, Chinese, and Ayurvedic traditions, represent the broader historical context in which exogenous acid supplementation arose: the recognition that gastric acidity is central to digestion.
Betaine hydrochloride is a short-acting acidifying agent, available over the counter in capsule form. Mealtime acid supplementation has an historic basis and could ameliorate many conditions related to insufficient gastric acid.
Regulatory history in the United States: Betaine hydrochloride used to be included in over-the-counter products as a "stomach acidifier and digestive aid." A federal law that went into effect in 1993 banned betaine hydrochloride from use in OTC products because there wasn't enough evidence to classify it "generally recognized as safe and effective." Betaine hydrochloride is now available only as a dietary supplement whose purity and strength can vary. Specifically, US Code of Federal Regulations, Title 21, Section 310.540, which became effective in November 1993, banned the marketing of betaine hydrochloride as a digestive aid. Despite its ban in over-the-counter medications by the FDA in 1993, betaine hydrochloride remains available as a supplement and is often explored by those seeking alternative health solutions.
It is important to note that betaine anhydrous (trimethylglycine without the HCl component) has a distinct and separate regulatory history. The US Food and Drug Administration (FDA) approved betaine trimethylglycine (also known by the brand name Cystadane) for the treatment of homocystinuria, a disease caused by abnormally high homocysteine levels at birth. Specifically, the compound is indicated for the adjunctive treatment of homocystinuria, involving deficiencies or defects in cystathionine beta-synthase (CBS), 5,10-methylene-tetrahydrofolate reductase (MTHFR), or cobalamin cofactor metabolism. This approval applies to betaine anhydrous, not to betaine HCl.
Understanding the rationale for HCl supplementation requires an understanding of its endogenous physiological role. Hydrochloric acid secreted from gastric parietal cells generates the strongly acidic environment of the gastric lumen (pH <2), which kills food-derived bacteria, facilitates food digestion, and promotes absorption of minerals including phosphate, calcium, and iron.
The H⁺-K⁺-ATPase enzyme expressed in parietal cells regulates the exchange of cytoplasmic H⁺ for extracellular K⁺. The H⁺ secreted into the gastric lumen by the H⁺-K⁺-ATPase combines with luminal Cl⁻ to form gastric acid, HCl. When stimulated, parietal cells secrete HCl at a concentration of roughly 160 mM (equivalent to a pH of 0.8). The hydrogen ion concentration in parietal cell secretions is roughly 3 million fold higher than in blood, and chloride is secreted against both a concentration and electric gradient.
HCl is necessary for the conversion of inactive pepsinogen to active pepsin, which helps with protein digestion in the stomach and the release of cobalamin (vitamin B12) from its salivary R-protein carrier. Pepsinogen is the inactive form of a proteolytic enzyme called pepsin, which is needed to digest proteins into small units called polypeptides. The zymogen pepsinogen only becomes activated by the gastric acid produced by the parietal cells. This mechanism acts as a safety measure to ensure the proteins found outside of the gastric lumen are not digested inappropriately.
Parietal cells also secrete intrinsic factor, which is essential in the absorption of vitamin B12 distally in the digestive tract by enterocytes of the terminal ileum.
Gastric acid secretion is regulated by multiple neuroendocrine signals. Gastric acid secretion is stimulated by several factors, including the release of acetylcholine (ACh) from the vagus nerve and the hormone gastrin from G cells in response to food intake. Gastrin is capable of indirectly and directly increasing HCl production by two mechanisms. The first is by stimulation of the ECL-like cells to release histamine, which then potentiates parietal cells. The second is by direct stimulation of the parietal cells themselves.
The integrative and functional medicine community has long considered inadequate levels of stomach acid, pancreatic enzymes and/or bile acid secretion to greatly contribute to an individual's risk for maldigestion or malabsorption. Routine mealtime "replacement" of one or more of these agents is commonly recommended by such practitioners to improve digestion and absorption.
Hypochlorhydria has several recognized clinical causes. Atrophy of the gastric mucosa is the endpoint of chronic gastritis. It has been associated with two primary causes: chronic Helicobacter pylori (H. pylori) infection and autoimmunity directed against gastric glandular cells, called autoimmune gastritis. Since stomach acid production decreases with age, the prevalence of atrophic gastritis is increased in people over age 60.
Autoimmune atrophic gastritis is an immune-mediated disease resulting in autoimmune destruction of the specialized acid-producing gastric parietal cells. As a consequence, in autoimmune atrophic gastritis, gastric acid secretion is irreversibly impaired, and the resulting hypochlorhydria leads to the main clinical manifestations and is linked, directly or indirectly, to the long-term neoplastic complications of this disease.
The prevalence of hypochlorhydria varies considerably across populations and measurement methodologies. While aging is regularly associated with decreased gastric acid production, fasting hypochlorhydria is reported to be less common (~10% or less) in elderly American subjects, while it is reported to be more common (>60%) in elderly Japanese subjects, and as high as 80% in a small cohort of Norwegian subjects in their eighth and ninth decades of life (average age: 84 years, range: 80–91). These studies illustrate the lack of consensus in the literature for the prevalence of fasting hypochlorhydria and achlorhydria in the aging population, as many factors are likely to affect fasting gastric pH.
Autoimmune gastritis is considered a relatively rare condition compared to other gastrointestinal disorders, with a prevalence estimated between 0.3% and 2.7% in the general population.
Even when the intake of nutrients is sufficient, the inadequate digestion and/or absorption of macronutrients, micronutrients, or other therapeutic compounds from the diet can result in clinical consequences. These consequences include classic GI-related symptoms related to malabsorption, as well as a broad range of clinical and subclinical signs and symptoms.
Gastric acid is needed for the active absorption of iron, zinc, B complex vitamins, especially B12, and digestion of consumed proteins.
In the stomach, betaine hydrochloride separates into betaine and hydrochloric acid. The hydrochloric acid increases stomach acid. The betaine moiety (trimethylglycine) that is released as the HCl component dissociates has its own separate biochemical activity as a methyl donor, but this is distinct from the acidifying action. In human metabolism, betaine serves as a methyl donor, converting homocysteine to methionine, and has been used therapeutically as a treatment for homocysteinuria.
The acid-releasing capacity of the supplement is quantifiable: betaine HCl readily releases H⁺ in an aqueous environment at approximately 0.65 mmol per 100 mg. This means that a standard 650 mg capsule would theoretically deliver approximately 4.2 mmol of H⁺.
Betaine hydrochloride works by increasing the acidity of the stomach, which can help to improve digestion. It does this by supplementing the hydrochloric acid that is naturally produced in the stomach. The mechanism is direct and chemical: the proton released from betaine HCl upon dissolution lowers gastric pH transiently. Betaine hydrochloride is a short-acting acidifying agent, available over the counter in capsule form.
The downstream effects of restored gastric acidity are mechanistically logical. Hydrochloric acid from gastric parietal cells (or from supplementation) generates the strongly acidic environment of the gastric lumen (pH <2), which kills food-derived bacteria, facilitates food digestion, and promotes absorption of minerals including phosphate, calcium, and iron. Re-acidification also restores the activation cascade of pepsinogen to pepsin, enabling protein proteolysis to proceed efficiently.
The most methodologically robust published human data on betaine HCl concern its ability to transiently lower gastric pH in subjects rendered hypochlorhydric by proton pump inhibitors (PPIs).
Study 1 — Yago et al. (2013), Molecular Pharmaceutics: This pilot study evaluated the extent and time course of gastric re-acidification after a solid oral dosage form of anhydrous betaine HCl in healthy volunteers with pharmacologically induced hypochlorhydria. Six healthy volunteers with baseline normochlorhydria (fasting gastric pH <4) were enrolled in this single-period study. Hypochlorhydria was induced via 20 mg oral rabeprazole twice daily for four days. After gastric pH >4 was confirmed for 15 minutes, 1500 mg of betaine HCl was given orally with 90 mL of water and gastric pH was continuously monitored for 2 hours. Betaine HCl significantly lowered gastric pH by 4.5 (±0.5) units from 5.2 (±0.5) to 0.6 (±0.2) (P < 0.001) during the 30-minute interval after administration. The onset of effect was rapid, with a mean time to pH <3 of 6.3 (±4.3) minutes.
An important limitation of this study is duration: when the subjects' gastric pH remained above 4.0 for a minimum of 15 minutes, they were given 1,500 mg of betaine HCl with 250 mL of water and monitored for changes in gastric pH. Even when given 1500 mg of betaine HCl, most subjects had returned to their PPI-induced gastric hypochlorhydria in less than 75 minutes on an empty stomach. Furthermore, since 1500 mg of betaine HCl was less potent when a small (336 kcal) meal was consumed 10 minutes prior, this suggests that higher doses of betaine HCl dosed just before the meal may be needed to compensate for the average meal (600–1000 kcal).
Evidence strength: This is a small pilot study (n=6), using a pharmacological model of hypochlorhydria rather than pathological or age-related hypochlorhydria. The findings are proof-of-concept for transient chemical re-acidification but cannot be generalized to functional or disease-related hypochlorhydria.
Study 2 — Yago et al. (2014), The AAPS Journal: Many orally administered, small-molecule, targeted anticancer drugs, such as dasatinib, exhibit pH-dependent solubility and reduced drug exposure when given with acid-reducing agents. In this randomized, single-dose, three-way crossover study, healthy volunteers received dasatinib (100 mg) alone, after pretreatment with rabeprazole, and with 1500 mg BHCl after rabeprazole pretreatment, to determine if BHCl can enhance dasatinib absorption in hypochlorhydric conditions. Rabeprazole (20 mg b.i.d.) significantly reduced dasatinib Cmax and AUC0-∞ by 92 and 78%, respectively. However, coadministration of BHCl significantly increased dasatinib Cmax and AUC0-∞ by 15- and 6.7-fold, restoring them to 105 and 121%, respectively, of the control (dasatinib alone).
A follow-on study tested the same strategy with a different drug (atazanavir) and under fed conditions. This study evaluated whether betaine HCl supplementation could affect the absorption of atazanavir in healthy subjects (N=8) in whom hypochlorhydria was induced using rabeprazole (20 mg twice daily). The meal was administered at T0 followed by betaine HCl (1500 mg) ten minutes later and the drug five minutes after that. In this study, 1500 mg of betaine HCl was not shown to significantly improve the absorption of atazanavir in subjects with PPI-induced achlorhydria given a meal, though betaine HCl supplementation did decrease the gastric pH. An important caveat: meal context substantially confounds betaine HCl's ability to counteract PPI-induced absorption reductions.
Evidence strength: These are small, controlled crossover pharmacokinetic studies in healthy volunteers. They establish a pharmacological proof of concept but are not directly applicable to clinical supplementation contexts for digestive health in hypochlorhydric patients. The key limitation is that these studies used a pharmaceutical model of hypochlorhydria (PPI-induced), not physiologic or pathologic low acid. Sample sizes were small.
Betaine hydrochloride is typically used as a dietary supplement to enhance stomach acid levels, which some alternative medicine practitioners believe is important for proper digestion and nutrient absorption. The theory behind its use hinges on the belief that low stomach acid may lead to incomplete digestion, potentially resulting in various allergic reactions and digestive problems.
However, to date, only four small clinical trials examining the effects of betaine HCl on gastric pH values have been conducted. While some small studies suggest that betaine hydrochloride effectively increases stomach acid, these studies often lack rigorous scientific backing. Consequently, its effectiveness for the aforementioned conditions remains largely unverified by substantial research.
Low stomach acidity has been linked to impaired absorption of several nutrients. These include iron, vitamin B12, magnesium, vitamin C, and calcium. Supplements or other treatments that restore acid balance could be helpful, at least in theory. Unfortunately, there are no studies on betaine HCl and nutrient deficiencies.
Evidence strength: There are currently no published, adequately powered randomized controlled trials demonstrating that betaine HCl supplementation improves clinically meaningful digestive or nutritional outcomes in patients with pathological hypochlorhydria. The evidence base for this common indication is weak and largely theoretical or anecdotal.
Current management of autoimmune gastritis (AIG) is limited to iron and vitamin B12 replacement, as no disease-modifying therapies exist. The progressive hypochlorhydria reduces pepsin activity, impairs gastric motility, and promotes small intestinal bacterial overgrowth (SIBO), causing dyspeptic symptoms and micronutrient malabsorption. Furthermore, gastric hypoacidity increases N-nitroso compound formation and triggers hypergastrinemia, elevating risks for both gastric cancer and neuroendocrine tumors.
A clinical trial is investigating whether betaine hydrochloride (with pepsin) supplementation can restore gastric acidity and improve clinical outcomes in AIG. Researchers plan to evaluate its effects on gastrin levels, gastrointestinal symptoms, exhaled gas markers (NO, H₂S, H₂, CH₄), anemia parameters, endoscopic atrophy scores, and incidence of gastric complications. Mealtime acid supplementation has an historic basis and could ameliorate many AIG-related gastrointestinal symptoms. Theoretically, acidification could also reduce the potential for hypergastrinemia and the production of N-nitroso compounds, consequently reducing the risk of gastric cancers.
Evidence strength: This represents an area of active investigation. Clinical trials are registered but have not yet published results. The rationale is mechanistically grounded, but clinical evidence is currently absent.
Esophagectomy patients are left with significant anatomical changes to the GI tract, including the cutting of the vagus nerve, which regulates gastric secretions, gastric acid pH, and motility. A published case report (PubMed, 2024) described a clinical application: a 76-year-old male patient self-referred for nutritional management of chronic nausea, fatigue, weight loss, and dumping syndrome 9 months post-esophagectomy, which was not responsive to medications. A physical functional nutritional assessment suggested gastric hypochlorhydria. A digestive supplement, betaine hydrochloric acid with pepsin (BHClP), was introduced, and the patient ingested 1 capsule containing 500 mg betaine hydrochloride and 23.5 mg pepsin prior to protein-containing meals and reported a substantial decrease in GI symptoms while eating a regular diet with no limitations. After a few months, the patient discontinued BHClP, and GI symptoms and dumping syndrome returned, leading to a loss of 7.5% of his body weight. The patient reinitiated the supplement and GI symptoms dissipated, and weight was restored. BHClP provided metabolic therapeutic benefit to optimize the patient's oral intake, preventing further complications and malnutrition. The success with BHClP for this patient case suggests that more research is needed to fully realize the mechanisms and clinical usage.
Evidence strength: A single case report; no causal inferences can be drawn. The findings are hypothesis-generating only.
The primary body system associated with betaine HCl supplementation is the gastrointestinal tract. It is used as a dietary supplement to enhance stomach acid levels. It is commonly recommended for a variety of health concerns, including asthma, digestive issues, excess Candida, food allergies, hay fever, lupus, rheumatoid arthritis, and ulcers. However, scientific evidence supports only the direct chemical action of lowering gastric pH, not the downstream claims for these diverse conditions.
Gastric acid is needed for the active absorption of iron, zinc, B complex vitamins especially B12, and digestion of consumed proteins. The theoretical rationale for betaine HCl use in promoting nutrient absorption is therefore mechanistically grounded, but, as noted, no clinical trials have directly assessed betaine HCl's effect on nutrient absorption outcomes.
Hydrochloric acid secreted from gastric parietal cells generates the strongly acidic environment of the gastric lumen (pH <2), which kills food-derived bacteria, facilitates food digestion, and promotes absorption of minerals. Low gastric acidity is associated with alterations in the gastric microbiota. H. pylori-induced atrophic gastritis, autoimmune atrophic gastritis, and proton pump inhibitor use each result in hypochlorhydria and may cause specific changes to the composition of the gastric microbiota. The gastric microbiota present in these conditions may contribute towards the specific gastric tumour risk associated with each hypochlorhydric state.
Increased gastric pH from the use of acid-reducing agents, such as proton-pump inhibitors or H2-receptor antagonists, can significantly impact the absorption of weakly basic drugs that exhibit pH-dependent solubility. The research on betaine HCl's ability to restore absorption of such drugs represents the strongest human clinical evidence currently available for any application of this supplement.
The following dosages appear in published studies and referenced clinical sources. These are reported factually as they appear in the literature and are not recommendations.
The dose-response relationship in the context of true pathological hypochlorhydria during regular meals has not been established in published controlled trials.
Although Betaine HCl was banned by the US Food and Drug Administration (FDA) in 1993 for use as a gastric acid supplement because of insufficient evidence to classify it as "generally recognized as safe and effective" (US Code of Federal Regulations, Title 21, Section 310.540), it remains readily available in health food markets with or without a fixed dosage of pepsin. Betaine hydrochloride seems to be well tolerated. But there is not enough research to know what the common side effects may be.
Never open betaine HCl capsules — HCl is extremely acidic and will burn the mouth and esophagus. Betaine HCl should not be taken on an empty stomach; it should be used only with food.
Betaine hydrochloride should not be confused with betaine anhydrous. The FDA-approved betaine anhydrous product is approved for the treatment of high levels of homocysteine in the urine (homocystinuria), a symptom of some rare genetic diseases. Confusion between these two compounds is common, and has been noted in medication error reports.
Betaine HCl's strongest evidence (rated moderate) shows transient re-acidification in PPI-induced hypochlorhydria. It is not FDA-approved for any indication, and it is contraindicated in peptic ulcer disease, active gastritis, and concurrent NSAID use. Betaine HCl does not treat GERD. It does not replace PPIs in any guideline-supported indication. It is contraindicated in peptic ulcer disease. It does not have FDA approval for any specific indication. It does not have RCT-level evidence for improving general dyspepsia, "leaky gut," or broad digestive complaints.
In summary, the scientific literature supports a clear and reproducible chemical mechanism (transient lowering of gastric pH), confirms this mechanism in small human pharmacological studies, and provides pharmacokinetic evidence that restored acidity can rescue the absorption of certain pH-sensitive drugs. Evidence for clinically meaningful benefits in patients with pathological hypochlorhydria—including improvements in digestion, nutrient status, or disease outcomes—remains absent from the published peer-reviewed literature, with ongoing trials investigating these questions.
Health conditions that Hydrochloric acid may help support.
Body systems that Hydrochloric acid may help support.
Go back